Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment

References

• Keating GM. Posaconazole. Drugs 2005;65:1553-67
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006;50:2009-15
   PubMed Web of Science ®Google Scholar
• Krishna G, Tarif MA, Xuan F, et al. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008;28:1223-32
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2003;57:218-22
   Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003;47:2788-95
   PubMed Web of Science ®Google Scholar
• Gubbins PO, Krishna G, Sansone-Parsons A, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A. Pharmacokinetics of posaconazole in healthy volunteers: a meta-analysis of five phase 1 studies. Presented at: 41st American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition December 3--7, 2006 Anaheim, CA, 2006
   Google Scholar
• Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob Agents Chemother 2007;51:812-18
   PubMed Web of Science ®Google Scholar
• Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005;45:185-92
   PubMed Web of Science ®Google Scholar
• Lipp HP. Antifungal agents – clinical pharmacokinetics and drug interactions. Mycoses 2008;51(Suppl 1):7-18
   PubMedGoogle Scholar
• NOXAFIL® (posaconazole) oral suspension [prescribing information]. Kenilworth, NJ: Schering Corporation, May 2008
   Google Scholar
• Krishna G, Moton A, Ma L, et al. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-3
   PubMed Web of Science ®Google Scholar
• Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 2007;29:1862-86
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004;48:3543-51
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. Guidance for industry: pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf [Last accessed 30 June 2009]
   Google Scholar
• Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9
   PubMed Web of Science ®Google Scholar
• Shen JX, Krishna G, Hayes RN. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Common terminology criteria for adverse events v3.0 (CTCAE). Available from http://ctep.cancer.gov/reporting/ctc_v30.html [Last accessed 13 November 2007]
   Google Scholar
• Courtney R, Laughlin M, Gontz H, et al. Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease. Poster presented at: American Association of Pharmaceutical Scientists 2000 Annual Meeting and Exposition; October 29 to November 2, 2000, Indianapolis, IN
   Google Scholar
• Saha P, Kou JH. Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. Eur J Pharm Biopharm 2000;50:403-11
   PubMed Web of Science ®Google Scholar
• Diflucan® (fluconazole tablets) (fluconazole injection – for intravenous infusion only) (fluconazole for oral suspension) [prescribing information]. New York, NY: Pfizer Inc, August 2004
   Google Scholar
• Sporanox® (itraconazole) capsules [prescribing information]. Titusville, NJ: Janssen, June 2006
   Google Scholar
• Sporanox® (itraconazole) oral solution [prescribing information]. Raritan, NJ: Ortho Biotech Products, L.P., January 2004
   Google Scholar
• Sporanox® (itraconazole) injection [prescribing information]. Raritan, NJ: Ortho Biotech Products, LP, April 2001
   Google Scholar
• VFEND® I.V. (voriconazole) for injection, VFEND® tablets (voriconazole), VFEND® (voriconazole) for oral suspension [prescribing information]. New York, NY: Pfizer Inc, March 2008
   Google Scholar